Beyond the Cage: Enabling Organoid-Based Drug Development

In a landmark shift for biomedical research, the FDA is phasing out its long-standing requirement for animal testing in the development of monoclonal antibodies and other drugs. Announced in an April 10, 2025 statement, this move reflects growing confidence in advanced non-animal models—such as organoids and other in vitro systems—that more accurately predict human responses to new therapies. Enabled by the FDA Modernization Act of 2022, the policy allows the use of alternatives like cell-based assays and computer modeling to support safety and efficacy assessments during early drug developmen